Table 1.
Comparative demographics of patients with MG and controls
| Characteristics | MGFA Classification | Control | |||
|---|---|---|---|---|---|
| I | II | III | IV-V | ||
| NO. of samples(n) | 58 | 30 | 24 | 13 | 50 |
| Age (years) | 46.10 ± 9.45 | 43.80 ± 10.83 | 45.63 ± 10.94 | 48.23 ± 9.65 | 46.14 ± 9.89 |
| Female n (%) | 28 (48.3) | 15 (50.0) | 10 (54.2) | 5 (45.5) | 26 (52.0) |
| AChR Ab pos n (%) | 42 (72.4) | 20 (66.7) | 17 (70.8) | 7 (53.8) | NA |
| MuSK Ab pos n (%) | 3 (5.2) | 3 (10.0) | 4 (16.7) | 5 (38.5) | NA |
| Double negative n (%) | 13 (22.4) | 7 (23.3) | 3 (12.5) | 1 (7.7) | |
| Treatment | Pyridostigmine, 23 of 58 added oral Prednisone | Pyridostigmine, 25 of 28 added oral Prednisone | Pyridostigmine, IVIG, Subsequent oral prednisone | Pyridostigmine, IVIG, IV methylprednisolone |
NA |
MG myasthenia gravis, AChR Ab acetylcholine receptor antibody, MuSK Ab muscle-specific tyrosine kinase antibody, I to V according to Myasthenia Gravis Foundation of America (MGFA) clinical classification; NA not available